GSK secures global rights to Chimagen cancer drug in US$750 million deal
British pharmaceutical firm GSK announced on Tuesday its acquisition of global rights to a T-cell engager from Chengdu-based Chimagen Biosciences for treating multiple myeloma.
GSK Acquires Chimagen Drug Rights
British pharmaceutical giant GSK announced on Tuesday, 15 September 2026, an agreement to acquire global rights to a cancer drug from Chengdu-based Chimagen Biosciences. The deal is valued at up to US$750 million. This T-cell engager (TCE) targets multiple myeloma, a type of blood cancer.
GSK stated it will pay an undisclosed upfront fee, with further payments contingent on the drug's successful development and commercialisation.
Novel Cancer Treatment Development
The acquired T-cell engager works by directly binding T cells, a type of white blood cell, to cancer cells, thereby activating the immune system to attack the cancer. GSK indicated that Chimagen's new drug shows promise for improved tolerability and more durable results, addressing common side effects seen with current TCEs. The programme is scheduled to enter phase one clinical trials in 2027.
China's Growing Biotech Sector
This transaction is the latest in a series of significant licensing agreements involving Chinese biotechnology firms. Such deals demonstrate China's expanding role in the global biotechnology sector. The agreement's value, up to US$750 million, establishes a key valuation point for similar early-stage Chinese drug assets.
This pattern of international collaboration shows increasing maturity and innovation within China's pharmaceutical research and development capabilities.
Global pharmaceutical companies are actively seeking novel drug pipelines, and this deal confirms Chinese biotech as a significant source. This trend drives continued capital flows into the sector. The increasing competition for promising Chinese drug development programmes will likely influence valuations for biotech startups in the region through 2027.
This article is journalism, not investment advice; consult a licensed professional before making financial decisions. Market data is indicative, may be delayed, and should be verified with your broker or exchange before use.
Comments.
Comments are moderated. We remove what is unlawful, abusive or off-topic, and and you remain responsible for what you post.
Reader comments open soon. Until then, corrections and responses go to our newsroom, and we publish what we get wrong on Corrections.